This site is intended for Healthcare Professionals outside the US

MF
PV
  1. About PV
  2. Hydroxyurea Intolerance

Toxicities frequently compromise the ability to dose HU at therapeutic levels1

More than 1 out of every 8 PV patients receiving HU is intolerant to the drug based on ELN criteria2

Rate of HU intolerance2

Rate of Hydroxyurea (HU) Intolerance in Polycythemia Vera Patients – JAKAVI

Patients with HU intolerance or HU resistance have had limited therapeutic options

  • For 59% of patients with HU resistance/intolerance in a Phase III clinical trial, HU was nonetheless considered their best available treatment3*

Learn about the well-characterised safety profile of JAKAVI

Next: Clinical benefit in PV with JAKAVI

*Based on 112 patients with HU resistance/intolerance who were randomised to the best available therapy (BAT) arm of a Phase III clinical trial.3
ELN=European LeukemiaNET; HU=hydroxyurea.

References:

  1. Najean Y, Rain J-D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90(9):3370-3377.
  2. Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363-1369.
  3. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435.